Monitor Unbuzzd's retail rollout and sales traction in South Florida and Texas as early indicators of commercial viability. Absent current revenue data, the stock's movement will hinge on future updates about distribution scale and consumer adoption.
Price Chart
Executive Summary
Quantum BioPharma announced the appointment of Richard Buzbuzian as CEO of Unbuzzd Wellness Inc., its majority-owned consumer brand, marking a strategic push toward nationwide commercialization of its clinically validated hangover relief beverage, unbuzzd. The move signals a shift toward aggressive market expansion in high-consumption U.S. regions and potential exchange listing, though no financial results or revenue figures were disclosed.
Key Facts
- Richard Buzbuzian appointed CEO of Unbuzzd Wellness Inc., replacing John Duffy, who transitions to Product Consultant.
- Commercial rollout to begin in South Florida and Texas, with plans for nationwide distribution across retail and e-commerce channels.
- unbuzzd is backed by a peer-reviewed clinical study showing efficacy in accelerating alcohol metabolism and reducing hangover symptoms.
- Quantum BioPharma retains 19.84% ownership in Unbuzzd Wellness Inc. and is entitled to 7% royalties on sales until $250 million in cumulative payments, after which the royalty drops to 3%.
- No financial metrics (revenue, earnings, guidance) were disclosed in the press release.
Financial Impact
Unclear near-term financial impact — no revenue, earnings, or deal size disclosed. Potential future upside tied to Unbuzzd's commercial success and royalty stream.
Risk Factors
- Unproven commercial scalability despite ambitious rollout plans.
- Highly competitive functional beverage market with low barriers to entry.
- Forward-looking statements carry significant execution and market acceptance risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3279059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.24 (−27.97%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.24 (−27.51%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.24 (−27.51%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.24 (−31.50%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.24 (−44.00%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.24 (−39.78%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.24 (−39.78%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.24 (−35.26%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.24 (−27.27%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.24 (−27.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers